Close Menu
NCIJ Network NCIJ Network
    What's Hot

    Europeans dare to believe Trump could deliver security for Ukraine  – POLITICO

    November 22, 2026

    Powerful new weight-loss drug helps patients cut knee pain in half

    November 22, 2026

    Welsh Midwives told to expect fewer jobs as 2027 recruitment drive is paused

    November 22, 2026
    Facebook X (Twitter) Instagram
    Trending
    • Europeans dare to believe Trump could deliver security for Ukraine  – POLITICO
    • Powerful new weight-loss drug helps patients cut knee pain in half
    • Welsh Midwives told to expect fewer jobs as 2027 recruitment drive is paused
    • Theresa May ‘aghast’ at Burnham’s EU plans and says ‘Brexit is done’
    • There’s probably a cult hiding in plain sight on your high street. At last, Britain is confronting the problem | Rachael Reign
    • Astronomer Isabel Angelo hunts for odd signals in telescope data
    • The Trump-Putin alliance threatens every European country – yet gushing populists still cheer them | Steve Bloomfield
    • NASA’s powerful Moon rocket engine roars through a dramatic 200-second test
    • About
      • Our Team
      • Editorial Policy
      • Editorial Independence
      • International Support
    • Trust & Standards
      • AI Usage Policy
      • Conflict of Interest Policy
      • Corrections Policy
      • Ethics Policy
      • Fact-Checking Policy
      • Source Protection
    • Get Involved
      • Guide for Sources
      • Support Independent Journalism
    • Legal
      • Cookie Policy
      • Privacy Policy
      • Terms of Use
    Facebook X (Twitter) Instagram
    NCIJ Network NCIJ Network
    Sunday, November 22
    • Home
    • World
    • Ai
    • Business
    • Politics
    • Health
    • Crypto
    • Science
    • Technology
    • Cybersecurity
    • Defense & Security
    • Economy
    • Energy
    • Europe
    • More
      • Fact Check
      • Investigations
      • Opinion & Analysis
      • Environment
    NCIJ Network NCIJ Network
    Home»Science

    Powerful new weight-loss drug helps patients cut knee pain in half

    NCIJ NETWNCIJ NETWORKBy NCIJ NETWNCIJ NETWORKNovember 22, 2026 Science No Comments6 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    For people living with painful knee osteoarthritis (OA), even simple activities like walking, climbing stairs, or getting out of a chair can become a struggle. Excess body weight can make these challenges even worse. Now, two major clinical trials suggest that a powerful experimental weight-loss drug could provide substantial relief.

    The two phase 3 trials, led by Northwestern University, included more than 1,000 participants in total. People receiving the highest dose of retatrutide, an experimental injectable weight-loss medication, lost an average of about 25% of their body weight. When researchers combined the findings from both trials, they found that approximately two-thirds of participants treated with retatrutide reported a reduction in knee pain of at least 50%. By comparison, only 38% of those given a placebo experienced that level of relief.

    The benefits extended beyond weight loss and improved knee pain. Participants also showed reductions in blood pressure, blood lipid levels, and inflammation throughout the body.

    Findings from both studies were published on Nov. 8 in the New England Journal of Medicine.

    “The findings are really saying for people who are overweight and have OA, if you lose a significant amount of weight with this treatment, there is a good chance that you’re going to get a meaningful reduction in your knee pain,” said corresponding author Dr. Thomas Schnitzer, professor of physical medicine and rehabilitation, anesthesiology and medicine (rheumatology) at Northwestern University Feinberg School of Medicine.

    “A major factor is that you’re loading your knees less and therefore, there’s less pain and it allows you to increase your function.”

    Philip Conaghan, a study co-author and professor of musculoskeletal medicine at the University of Leeds in the United Kingdom, presented results from one of the trials, TRIUMPH-4, on Nov. 8 at the American College of Rheumatology annual meeting in Orlando, Florida. Findings from the second trial, TRIUMPH-1-OA, were scheduled for presentation during a separate poster session that same day.

    A Potential New Treatment for Millions With Knee Osteoarthritis

    Painful knee osteoarthritis affects approximately 5% of Americans (15 million people). Available treatments range from physical therapy and medications applied to the skin to oral anti-inflammatory drugs such as ibuprofen and Voltaren. Other options include opioids and corticosteroid injections, although the relief provided by steroid injections generally lasts only a short time.

    Weight loss is another established way to ease symptoms. Previous studies have shown that losing 5% to 10% of body weight through changes in diet and exercise can improve knee osteoarthritis pain. However, Schnitzer explained that losing more than 10% through these approaches alone is often challenging. For people already struggling with painful knees, exercising enough to achieve substantial weight loss can be especially difficult.

    Retatrutide could offer another approach. Developed by Eli Lilly, the experimental medication is administered as a once-weekly injection and works differently from existing GLP-1 medications such as semaglutide and tirzepatide.

    While those drugs act on one or two hormone receptors and typically produce weight reductions of 10% to 20%, retatrutide activates receptors associated with three different naturally occurring hormones. In the clinical trials, participants lost approximately 20% to 25% of their body weight, depending on the dose. Eli Lilly scientists also contributed to the research as study co-authors.

    “Participants had remarkable responses,” Schnitzer said. “Many of the people in this study lost considerable amounts of weight, with a few losing up to a hundred pounds or more.”

    Why Diet and Exercise Still Matter

    Despite the encouraging findings, Schnitzer emphasized that lifestyle changes should remain the starting point for people who are overweight and have painful knee osteoarthritis.

    Improving eating habits, increasing physical activity, and making other sustainable lifestyle adjustments can help reduce symptoms without the expense of newer weight-loss medications. These strategies also avoid side effects associated with GLP-1 drugs, including gastrointestinal problems and muscle loss.

    Maintaining muscle strength is particularly important for people with knee osteoarthritis because the muscles surrounding the joint help support and stabilize it. Losing too much muscle could therefore create additional challenges for patients who already have difficulty moving comfortably.

    For individuals who cannot achieve sufficient weight loss through lifestyle changes and continue to experience significant knee pain, Schnitzer believes retatrutide could become a valuable option if it receives approval from the U.S. Food and Drug Administration.

    Could the Drug Also Slow Knee Arthritis Progression?

    Although the trials demonstrated substantial improvements in weight and pain, several important questions remain unanswered.

    One of the biggest is whether retatrutide does more than relieve symptoms. Researchers still do not know if the drug can slow the underlying progression of knee osteoarthritis enough to reduce the likelihood that patients will eventually need knee replacement surgery. People who already required a knee replacement were excluded from the trials.

    “That would be the goal here to say you can reduce people’s pain, and you can stop the progression of their osteoarthritis,” Schnitzer said.

    Another unanswered question is whether retatrutide might benefit people with painful knee osteoarthritis who are not overweight. Because the trials did not include these patients, further studies will be needed to determine whether they could experience similar improvements.

    Researchers are also interested in understanding how much of the pain relief comes directly from weight loss and how much might be related to the drug’s effects on inflammation.

    “These drugs are believed to have significant anti-inflammatory activity, but the mechanism is not entirely known,” Schnitzer said. “Whether cutting down inflammation in the joint is also important in addition to reducing load needs more research, so this is still a first step, in my view. I’ve been working in the OA field for a long time, and I think this opens up opportunities to do a lot more studies to understand the condition better.”

    How Researchers Measured Knee Pain Relief

    To evaluate changes in symptoms, the research teams used the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain index, a standardized tool for assessing osteoarthritis pain.

    During study visits, participants rated their pain on a scale from 0 to 10. They also used a mobile app to record their pain levels each day, allowing researchers to track how symptoms changed throughout treatment.

    The study is titled, “Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity.”

    cut drug helps knee pain patients powerful weightloss
    NCIJ NETWNCIJ NETWORK
    • Website

    Keep Reading

    Astronomer Isabel Angelo hunts for odd signals in telescope data

    NASA’s powerful Moon rocket engine roars through a dramatic 200-second test

    This scientist proves which problems computers can’t solve quickly

    Scientists say the human family tree may need a radical rewrite

    What helps land recover after fire? This ecologist looks to the past

    How do scientists learn from failure? This researcher has clues

    Add A Comment
    Leave A Reply Cancel Reply

    Editors Picks

    Europeans dare to believe Trump could deliver security for Ukraine  – POLITICO

    November 22, 2026

    Powerful new weight-loss drug helps patients cut knee pain in half

    November 22, 2026

    Welsh Midwives told to expect fewer jobs as 2027 recruitment drive is paused

    November 22, 2026

    Theresa May ‘aghast’ at Burnham’s EU plans and says ‘Brexit is done’

    November 22, 2026
    Latest Posts

    Unpacking claim USS Doris Miller will be renamed after Trump instead of Black WWII hero

    August 21, 2026

    Iran Vows ‘Devastating’ Retaliation Against New U.S. Sanctions Threats

    August 21, 2026

    Bomb Fishing Is Reducing Coral Reefs to ‘Rubble’

    August 21, 2026

    Subscribe to News

    Get the latest sports news from NewsSite about world, sports and politics.

    NCIJ Network is an independent digital news platform delivering trusted investigative journalism, European and global news, in-depth analysis, and fact-based reporting with accuracy, transparency, and integrity.

    Facebook X (Twitter) Instagram Pinterest YouTube

    Europeans dare to believe Trump could deliver security for Ukraine  – POLITICO

    November 22, 2026

    Powerful new weight-loss drug helps patients cut knee pain in half

    November 22, 2026

    Welsh Midwives told to expect fewer jobs as 2027 recruitment drive is paused

    November 22, 2026

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    Type above and press Enter to search. Press Esc to cancel.